Publications & Presentations

Check out the latest scientific presentations from Kailera Therapeutics.

Phase 3 Trial of HRS9531, a GLP-1/GIP Receptor Agonist, in Chinese Adults with Overweight or Obesity

X. Li et al.
ObesityWeek® 2025
November 2025

Efficacy and safety of a novel oral small molecule GLP1RA (HRS-7535) in Chinese patients with type 2 diabetes inadequately controlled by metformin and SGLT2 inhibitor

M. Ren et al.
European Association for the Study of Diabetes (EASD)
September 2025

Efficacy and Safety of HRS9531, a Novel Dual GLP1/GIP Receptor Agonist, in Chinese Adults with Overweight or Obesity Without Diabetes

Q. Wen et al.
European Association for the Study of Diabetes (EASD)
September 2025

Efficacy and Safety of a Novel Oral Small Molecule Glucagon Like Peptide 1 Receptor Agonist (HRS-7535) in Type 2 Diabetes Mellitus Patients Inadequately Controlled by Metformin

L. Guo et al.
American Diabetes Association (ADA) 2025
June 2025

Efficacy and Safety of a Novel Oral Small Molecule GLP-1RA in Chinese Obese Adults without Diabetes

W. Gu et al.
American Diabetes Association (ADA) 2025
June 2025

Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist in Participants with Type 2 Diabetes Mellitus Up to 32 Weeks

J. Zhao et al.
American Diabetes Association (ADA) 2025
June 2025

Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist (HRS9531), in Obese Adults without Diabetes: Up to 52-Week Treatment

L. Zhao et al.
American Diabetes Association (ADA) 2025
June 2025

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 Tablet, an Oral Dual GLP-1/GIP Receptor Agonist, in Healthy Participants: A Phase 1 Study

W. Hu et al.
American Diabetes Association (ADA) 2025
June 2025

Efficacy and Safety of a Novel Dual GLP-1/GLP Receptor Agonist in Chinese Overweight or Obese Adults without Diabetes

J. Zhou et al.
American Diabetes Association (ADA) 2025
June 2025